LJLeisa Johnson

Leisa Johnson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Leisa Johnson has a total of 54 co-authors. Here are the top co-authors by number of shared publications:

  • Anthony Lima

    Genentech Inc., South San Francisco, California, USA. 2Cell Microscopy Center, Department of Cell Biology, University Medical Center Utrecht and Institute for Biomembranes, Utrecht, the Netherlands

    2 shared publications
  • Ian Kasman

    Genentech Inc., South San Francisco, California, USA. 2Cell Microscopy Center, Department of Cell Biology, University Medical Center Utrecht and Institute for Biomembranes, Utrecht, the Netherlands

    2 shared publications
  • Rafael Molina

    Genentech Inc., South San Francisco, California, USA. 2Cell Microscopy Center, Department of Cell Biology, University Medical Center Utrecht and Institute for Biomembranes, Utrecht, the Netherlands

    2 shared publications
  • Aaron Boudreau

    Department of Discovery Oncology, Genentech Inc, 1 DNA Way, 94080 South San Francisco, CA USA

    1 shared publication
  • Adrian M Jubb

    Genentech Inc., 1 DNA Way, South San Francisco, CA, USA

    1 shared publication
  • Adrian M. Jubb

    Genentech Inc., South San Francisco, California, USA. 2Cell Microscopy Center, Department of Cell Biology, University Medical Center Utrecht and Institute for Biomembranes, Utrecht, the Netherlands

    1 shared publication

Latest Publications

  • Open Access

    Metabolic and transcriptional profiling reveals pyruvate dehydrogenase kinase 4 as a mediator of epithelial-mesenchymal transition and drug resistance in tumor cells

    by Yuting Sun, Anneleen Daemen, Georgia Hatzivassiliou, David Arnott, Catherine Wilson, Guanglei Zhuang, Min Gao, Peter Liu, Aaron Boudreau, Leisa Johnson, et al.

    Accumulating preclinical and clinical evidence implicates epithelial-mesenchymal transition (EMT) in acquired resistance to anticancer drugs; however, mechanisms by which the mesenchymal state determines drug resistance remain unknown. To explore a potential role for altered cellular metabolism in EMT and associated drug resistance, we analyzed the metabolome and transcriptome of three lung cancer cell lines that were rendered drug resistant following experimental induction of EMT. This analysis revealed evidence of metabolic rewiring during EMT that diverts glucose to the TCA cycle. Such rewiring was at least partially mediated by the reduced expression of pyruvate dehydrogenase kinase 4 (PDK4), which serves as a gatekeeper of the TCA cycle by inactivating pyruvate dehydrogenase (PDH). Overexpression of PDK4 partially blocked TGFβ-induced EMT; conversely, PDK4 inhibition via RNAi-mediated knockdown was sufficient to drive EMT and promoted erlotinib resistance in EGFR mutant lung cancer cells. We identified a novel interaction between PDK4 and apoptosis-inducing factor (AIF), an inner mitochondrial protein that appears to play a role in mediating this resistance. In addition, analysis of human tumor samples revealed PDK4-low as a predictor of poor prognosis in lung cancer and that PDK4 expression is dramatically downregulated in most tumor types. Together, these findings implicate PDK4 as a critical metabolic regulator of EMT and associated drug resistance.


  • Open Access

    Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacy

    by Leisa Johnson, Mahrukh Huseni, Tanya Smyczek, Anthony Lima, Stacey Yeung, Jason H. Cheng, Rafael Molina, David Kan, Ann De Mazière, Judith Klumperman, et al.

    Many oncology drugs are administered at their maximally tolerated dose without the knowledge of their optimal efficacious dose range. In this study, we describe a multifaceted approach that integrated preclinical and clinical data to identify the optimal dose for an antiangiogenesis agent, anti-EGFL7. EGFL7 is an extracellular matrix–associated protein expressed in activated endothelium. Recombinant EGFL7 protein supported EC adhesion and protected ECs from stress-induced apoptosis. Anti-EGFL7 antibodies inhibited both of these key processes and augmented anti-VEGF–mediated vascular damage in various murine tumor models. In a genetically engineered mouse model of advanced non–small cell lung cancer, we found that anti-EGFL7 enhanced both the progression-free and overall survival benefits derived from anti-VEGF therapy in a dose-dependent manner. In addition, we identified a circulating progenitor cell type that was regulated by EGFL7 and evaluated the response of these cells to anti-EGFL7 treatment in both tumor-bearing mice and cancer patients from a phase I clinical trial. Importantly, these preclinical efficacy and clinical biomarker results enabled rational selection of the anti-EGFL7 dose currently being tested in phase II clinical trials.


  • Anti‐VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models

    by Mallika Singh, Suzana S Couto, William F Forrest, Anthony Lima, Jason H Cheng, Rafael Molina, Jason E Long, Patricia Hamilton, Angela McNutt, Ian Kasman, et al.

    Resistance to anti‐angiogenic therapy can occur via several potential mechanisms. Unexpectedly, recent studies showed that short‐term inhibition of either VEGF or VEGFR enhanced tumour invasiveness and metastatic spread in preclinical models. In an effort to evaluate the translational relevance of these findings, we examined the consequences of long‐term anti‐VEGF monoclonal antibody therapy in several well‐validated genetically engineered mouse tumour models of either neuroendocrine or epithelial origin. Anti‐VEGF therapy decreased tumour burden and increased overall survival, either as a single agent or in combination with chemotherapy, in all four models examined. Importantly, neither short‐ nor long‐term exposure to anti‐VEGF therapy altered the incidence of metastasis in any of these autochthonous models, consistent with retrospective analyses of clinical trials. In contrast, we observed that sunitinib treatment recapitulated previously reported effects on tumour invasiveness and metastasis in a pancreatic neuroendocrine tumour (PNET) model. Consistent with these results, sunitinib treatment resulted in an up‐regulation of the hypoxia marker GLUT1 in PNETs, whereas anti‐VEGF did not. These results indicate that anti‐VEGF mediates anti‐tumour effects and therapeutic benefits without a paradoxical increase in metastasis. Moreover, these data underscore the concept that drugs targeting VEGF ligands and receptors may affect tumour metastasis in a context‐dependent manner and are mechanistically distinct from one another. Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.